InsiderTrades.com logo
WARNING: “Buffett Indicator” flashing for first time in 50 years
From Behind the Markets   |   Ad
Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Take these 4 steps today to protect your retirement NOW
Joseph E. Gilliam net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Joseph Gilliam Biography and Net Worth

CFO of Glaukos
Mr. Gilliam has served as our chief financial officer and senior vice president, corporate development since May 2017. He has nearly 20 years of experience across capital markets, strategic advisory, finance and banking services with an emphasis on the life sciences industry, including the medical technology, diagnostics and biotechnology sectors. From 2013 to May 2017, he was a managing director in the healthcare investment banking group at JPMorgan, where he led the Glaukos initial public offering for the firm. From 2001 to 2013, Mr. Gilliam held increasingly responsible positions at JPMorgan, with experience spanning mergers and acquisitions, primary and secondary public equity offerings, bank lending, bond offerings and other transactions. His prior experience includes positions at The Beacon Group (which was combined with JPMorgan and Chase Manhattan in 2001) and PricewaterhouseCoopers. Mr. Gilliam has a B.S. in accounting from the Kelly School of Business at Indiana University.

What is Joseph E. Gilliam's net worth?

The estimated net worth of Joseph E. Gilliam is at least $15.42 million as of October 30th, 2024. Mr. Gilliam owns 102,169 shares of Glaukos stock worth more than $15,415,259 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Gilliam may own. Additionally, Mr. Gilliam receives a salary of $1,180,000.00 as CFO at Glaukos. Learn More about Joseph E. Gilliam's net worth.

How old is Joseph E. Gilliam?

Mr. Gilliam is currently 48 years old. There are 5 older executives and no younger executives at Glaukos. Learn More on Joseph E. Gilliam's age.

What is Joseph E. Gilliam's salary?

As the CFO of Glaukos Co., Mr. Gilliam earns $1,180,000.00 per year. Learn More on Joseph E. Gilliam's salary.

How do I contact Joseph E. Gilliam?

The corporate mailing address for Mr. Gilliam and other Glaukos executives is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. Glaukos can also be reached via phone at (949) 367-9600 and via email at [email protected]. Learn More on Joseph E. Gilliam's contact information.

Has Joseph E. Gilliam been buying or selling shares of Glaukos?

Joseph E. Gilliam has not been actively trading shares of Glaukos during the last quarter. Learn More on Joseph E. Gilliam's trading history.

Who are Glaukos' active insiders?

Glaukos' insider roster includes Thomas Burns (CEO), Mark Foley (Director), Joseph Gilliam (CFO), Gilbert Kliman (Director), Marc Stapley (Director), Alex Thurman (CFO), and Aimee Weisner (Director). Learn More on Glaukos' active insiders.

Are insiders buying or selling shares of Glaukos?

During the last year, insiders at the medical instruments supplier sold shares 38 times. They sold a total of 478,700 shares worth more than $45,158,980.23. The most recent insider tranaction occured on December, 11th when Director Gilbert H Kliman sold 2,000 shares worth more than $288,020.00. Insiders at Glaukos own 6.4% of the company. Learn More about insider trades at Glaukos.

Information on this page was last updated on 12/11/2024.

Joseph E. Gilliam Insider Trading History at Glaukos

See Full Table

Joseph E. Gilliam Buying and Selling Activity at Glaukos

This chart shows Joseph E. Gilliam's buying and selling at Glaukos by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Glaukos Company Overview

Glaukos logo
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Read More

Today's Range

Now: $150.88
Low: $141.53
High: $151.12

50 Day Range

MA: $138.05
Low: $127.60
High: $150.88

2 Week Range

Now: $150.88
Low: $74.75
High: $151.12

Volume

1,054,006 shs

Average Volume

576,626 shs

Market Capitalization

$8.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03
WARNING: “Buffett Indicator” flashing for first time in 50 years
From Behind the Markets   |   Ad
Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Take these 4 steps today to protect your retirement NOW